Artificial Intelligence for Vision Impairment from Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This pragmatic clinical trial is being conducted to test the effectiveness of AI in improving screening and follow-up eye care compared to usual-care among patients with diabetes across 4 primary care clinics. This is an autonomous AI-based screening to detect diabetic eye disease at primary care visits.
Who Is on the Research Team?
Roomsa Channa, MD
Principal Investigator
University of Wisconsin, Madison
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
A 6-week baseline period is conducted in all clinics to establish initial conditions
Intervention
A 4-month intervention period where AI-based screening is implemented in selected clinics
Follow-up
Participants are monitored for completion of follow-up eye care within 5 months of recommendation
What Are the Treatments Tested in This Trial?
Interventions
- AI
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
AI intervention includes (1) acquisition of eye photos and (2) autonomous (i.e. without human oversight) AI-based identification of referrable or non-referrable eye disease at the primary care clinic.
Patients with diabetes will follow the clinic's usual practice, in which the primary care provider recommends an annual screening eye exam for patients with diabetes. This requires the patient to make a separate visit to see an eye care provider. Clinic staff will provide scheduling assistance per the standard scheduling procedure for the clinic.
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Wisconsin, Madison
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.